DT-200 - A Selective Androgen Receptor Modulator to Improve Muscle Strength & Function in Duchenne


Frequently Asked Questions (FAQs) about this research:


What stage is this research?

  • The DT-200 development program has completed 3 initial phase 1 trials in 78 healthy adult volunteers. These studies showed that the SARM is safe and well tolerated for up to 14 days treatment. Testing in Duchenne has not yet begun.


Where is this research being done and who is funding this research?

  • DT-200 is wholly owned by Akashi Therapeutics, who are leading the clinical development program. Akashi is currently seeking funding for the next development step, a 4-week Proof of Concept Clinical (POC) trial.


What is the goal or purpose of this research?

  • DT-200 is a selective androgen receptor modulator (SARM).  Selective androgen receptor modulators (SARMs) have been developed to mimic the muscle building effects of androgens (testosterone), without their undesirable side effects. Akashi hopes that the more precise action of this drug will confer better long term safety and tolerability in both adult and pediatric muscle diseases compared to androgens. DT-200 is effective in multiple animal models, including mice that lack dystrophin.  Importantly, compared to other SARMs in clinical development, DT-200 shows significantly greater preference for skeletal muscle. Accordingly, Akashi plans to develop DT-200 with the objective of improving muscle strength and function in both adult muscle diseases, such as Charcot Marie Tooth disease (CMT) and Facioscapulohumeral Muscular Dystrophy (FSHD), and in pediatric neuromuscular diesease, such as Duchenne and Spinal Muscle Atrophy (SMA).


What is the current state of this research and what steps need to be completed before moving into a clinical trial?

  • Three phase 1 studies with DT-200 were successfully completed in Belgium and Germany, having confirmed the product is safe and well tolerated at the once daily oral dose of 0.5 mg. Akashi met with the UK Regulatory Agency (MHRA) for scientific advice and input into the design of a Proof of Concept clinical trial. Akashi plans to initiate this 4-week POC trial in the UK in healthy adult volunteers. The main objective of the POC trial is first to evaluate DT-200’s ability to increase mass, strength and function of healthy muscle.  It is anticipated the POC trial will take approximately 9 months to complete. All initial formulation development and testing work has been completed to allow start of this study in 2nd half of 2017.


What is your best estimate for the length of time it will take to move this research into clinical trials?

  • If the POC trial in healthy adult subjects is positive, Akashi anticipates initiation of clinical trials in adult and pediatric muscle diseases within 12 months from the conclusion of the POC trial.


Where would a clinical trial take place?

  • Phase II trials would be initiated in both the US and Europe.


Who would be eligible to participate in a clinical trial?

  • It is too early to know what the inclusion criteria would be for a future clinical trial. This drug could be beneficial for all DMD boys regardless of specific Glossary Link mutation.


Where can I learn more about this research?

  • You can learn more about DT-200 (and other Akashi initiatives) by consulting the Akashi website at: http://akashirx.com 
  • www.ClinicalTrials.gov will post all DT-200 clinical trials once they are actively recruiting subjects.


(Updated 5/5/2017)